Recursion Pharmaceuticals, Inc. Class A RXRX

HubSpot sits 29 places higher at No. 57 in the Roundtable 100 this week.

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.

Goldman Sachs’ Neutral initiation of Tempus AI, Inc. (NASDAQ:TEM) on September 21 puts the company’s fastest-growing businesses under different tests: diagnostics offers visible near-term growth, while the data and applications segment faces renewal risk as several major contracts approach extensions over the next two years. The timing is notable because Tempus AI, Inc. (NASDAQ:TEM) announced […]

Recursion Pharmaceuticals (RXRX) is back on traders’ screens after a sharp daily move, with the share price closing at US$3.83. Recent returns have been mixed over the past week and month. For context, Recursion Pharmaceuticals has delivered an 8.19% 1-day share price return and a 19.69% 7-day share price return, yet the total shareholder return over the past year is down 22%. This hints at short-term momentum building against a more difficult long-term backdrop and shifting views on the...

Don't catch a falling knife.

Contineum Therapeutics (CTNM), Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making

Wolfspeed, BigBear.ai and Others Face Heavy Short-Seller Pressure